Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10782684 | 0.83 | SMN1; SMN2 (0.52) | MAPTTDP1SMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL31314406 | 0.83 | SMN1; SMN2 (0.52) | MAPTTDP1SMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL10700607 | 0.74 | TDP1 (0.46) | MAPTTDP1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2232787 | 0.74 | GAA (0.56) | MAPTTDP1SMN1; SMN2GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1752687 | 0.73 | TDP1 (0.45) | MAPTTDP1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2855474 | 0.73 | TDP1 (0.52) | MAPTTDP1GAAALDH1A1CASP1 | |
| SCHEMBL11320359 | 0.73 | GNG2 (0.53) | MAPTTDP1SMN1; SMN2ALDH1A1CFTR | |
| SCHEMBL9136264 | 0.72 | GPR35 (0.53) | MAPTTDP1SMN1; SMN2CFTRMEN1 | |
| SCHEMBL3247556 | 0.72 | TDP1 (0.43) | MAPTTDP1SMN1; SMN2ALDH1A1CASP1 | |
| SCHEMBL9515087 | 0.72 | RAB9A (0.55) | MAPTTDP1SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409463-B1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1242385-B1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | MORIARTY KEVIN J | 2005-10-27 | — | — | US | disclosed |
| US-6906067-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1409463-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | Bristol-Myers Squibb Company (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003002542-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-09 | — | — | WO | disclosed |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | PHARMACEOPEIA, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1242385-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | PHARMACOPEIA, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001047897-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | MAPT 3179/4885TDP1 2607/4885SMN1; SMN2 2577/4885 |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | MAPT 3376/4885TDP1 2228/4885SMN1; SMN2 2454/4885 |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | MAPT 3376/4885TDP1 2228/4885SMN1; SMN2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.